Simultaneous Quantification of BCR-ABL and Bruton Tyrosine Kinase Inhibitors in Dried Plasma Spots and Its Application to Clinical Sample Analysis

被引:10
作者
Mukai, Yuji [1 ,2 ]
Yoshida, Yuka [1 ]
Yoshida, Tatsunari [3 ]
Kondo, Takeshi [4 ]
Inotsume, Nobuo [1 ,5 ]
Toda, Takaki [1 ]
机构
[1] Hokkaido Univ Sci, Dept Clin Pharmacol, Fac Pharmaceut Sci, Sapporo, Hokkaido 0068585, Japan
[2] Univ Tsukuba Hosp, Dept Pharm, Ibaraki, Japan
[3] Biotage Japan Ltd, Tokyo, Japan
[4] Aiiku Hosp, Blood Disorders Ctr, Dept Hematol, Sapporo, Hokkaido, Japan
[5] Nihon Pharmaceut Univ, Saitama, Japan
关键词
dried plasma spot; tyrosine kinase inhibitor; therapeutic drug monitoring; mass spectrometry; liquid chromatography; CHRONIC MYELOID-LEUKEMIA; LC-MS/MS; BLOOD SPOT; IMATINIB PHARMACOKINETICS; PONATINIB; NILOTINIB; IBRUTINIB; RECOMMENDATIONS; BIOANALYSIS; VALIDATION;
D O I
10.1097/FTD.0000000000000825
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Recent reports highlight the importance of therapeutic drug monitoring (TDM) of BCR-ABL and Bruton tyrosine kinase inhibitors (TKIs); thus, large-scale studies are needed to determine the target concentrations of these drugs. TDM using dried plasma spots (DPS) instead of conventional plasma samples is a promising approach. This study aimed to develop and validate a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the simultaneous quantification of BCR-ABL and Bruton TKIs for further TDM studies. Methods: A 20-mu L aliquot of plasma was spotted onto a filter paper and dried completely. Analytes were extracted from 2 DPS using 250 mu L of solvent. After cleanup by supported liquid extraction, the sample was analyzed by LC-MS/MS. Applicability of the method was examined using samples of patients' DPS transported by regular mail as a proof-of-concept study. The constant bias and proportional error between plasma and DPS concentrations were assessed by Passing-Bablok regression analysis, and systematic errors were evaluated by Bland-Altman analysis. Results: The method was successfully validated over the following calibration ranges: 1-200 ng/mL for dasatinib and ponatinib, 2-400 ng/mL for ibrutinib, 5-1000 ng/mL for bosutinib, and 20-4000 ng/mL for imatinib and nilotinib. TKI concentrations were successfully determined for 93 of 96 DPS from clinical samples. No constant bias between plasma and DPS concentrations was observed for bosutinib, dasatinib, nilotinib, and ponatinib, whereas there were proportional errors between the plasma and DPS concentrations of nilotinib and ponatinib. Bland-Altman plots revealed that significant systematic errors existed between both methods for bosutinib, nilotinib, and ponatinib. Conclusions: An LC-MS/MS method for the simultaneous quantification of 6 TKIs in DPS was developed and validated. Further large-scale studies should be conducted to assess the consistency of concentration measurements obtained from plasma and DPS.
引用
收藏
页码:386 / 393
页数:8
相关论文
共 42 条
[1]   Therapeutic drug monitoring of ponatinib using a simple high-performance liquid chromatography method in Japanese patients [J].
Abumiya, Maiko ;
Miura, Masatomo ;
Takahashi, Naoto .
LEUKEMIA RESEARCH, 2018, 64 :42-45
[2]  
[Anonymous], 2009, Guideline on Bioanalytical Method Validation EMEA/CHMP/EWP/192217/
[3]   DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application [J].
Antunes, Marina Venzon ;
Raymundo, Suziane ;
Wagner, Sandrine Comparsi ;
Mattevi, Vanessa Sune ;
Vieira, Natalia ;
Leite, Renata ;
Reginato, Fabiola ;
Capra, Marcelo Zanella ;
Fogliatto, Laura ;
Linden, Rafael .
BIOANALYSIS, 2015, 7 (16) :2105-2117
[4]   Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL [J].
Barr, Paul M. ;
Brown, Jennifer R. ;
Hillmen, Peter ;
O'Brien, Susan ;
Barrientos, Jacqueline C. ;
Reddy, Nishitha M. ;
Coutre, Steven ;
Mulligan, Stephen P. ;
Jaeger, Ulrich ;
Furman, Richard R. ;
Cymbalista, Florence ;
Montillo, Marco ;
Dearden, Claire ;
Robak, Tadeusz ;
Moreno, Carol ;
Pagel, John M. ;
Burger, Jan A. ;
Suzuki, Samuel ;
Sukbuntherng, Juthamas ;
Cole, George ;
James, Danelle F. ;
Byrd, John C. .
BLOOD, 2017, 129 (19) :2612-2615
[5]   Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and Δ(4)-abiraterone from cancer patients [J].
Bhatnagar, Atul ;
McKay, Matthew J. ;
Thaysen-Andersen, Morten ;
Arasaratnam, Malmaruha ;
Crumbaker, Megan ;
Gurney, Howard ;
Molloy, Mark P. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2019, 1126
[6]   Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling [J].
Boons, Christel C. L. M. ;
Chahbouni, Abdel ;
Schimmel, Anneliene M. ;
Wilhelm, Abraham J. ;
den Hartog, Yvonne M. ;
Janssen, Jeroen J. W. M. ;
Hendrikse, N. Harry ;
Hugtenburg, Jacqueline G. ;
Swart, Eleonora L. .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2017, 69 (10) :1265-1274
[7]   Development and validation of UHPLC-MS/MS methods for the quantification of colistin in plasma and dried plasma spots [J].
Cangemi, Giuliana ;
Barco, Sebastiano ;
Castagnola, Elio ;
Tripodi, Gino ;
Favata, Fabio ;
D'Avolio, Antonio .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2016, 129 :551-557
[8]   Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology Guideline: Development and Validation of Dried Blood Spot-Based Methods for Therapeutic Drug Monitoring [J].
Capiau, Sara ;
Veenhof, Herman ;
Koster, Remco A. ;
Bergqvist, Yngve ;
Boettcher, Michael ;
Halmingh, Otto ;
Keevil, Brian G. ;
Koch, Birgit C. P. ;
Linden, Rafael ;
Pistos, Constantinos ;
Stolk, Leo M. ;
Touw, Daan J. ;
Stove, Christophe P. ;
Alffenaar, Jan-Willem C. .
THERAPEUTIC DRUG MONITORING, 2019, 41 (04) :409-430
[9]   Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias [J].
Cortes, Jorge E. ;
Kantarjian, Hagop ;
Shah, Neil P. ;
Bixby, Dale ;
Mauro, Michael J. ;
Flinn, Ian ;
O'Hare, Thomas ;
Hu, Simin ;
Narasimhan, Narayana I. ;
Rivera, Victor M. ;
Clackson, Tim ;
Turner, Christopher D. ;
Haluska, Frank G. ;
Druker, Brian J. ;
Deininger, Michael W. N. ;
Talpaz, Moshe .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (22) :2075-2088
[10]   Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography [J].
Davies, Andrea ;
Hayes, Alison K. ;
Knight, Katy ;
Watmough, Sarah J. ;
Pirmohamed, Munir ;
Clark, Richard E. .
LEUKEMIA RESEARCH, 2010, 34 (06) :702-707